This was supported by reports validating the effect of EGCG on breast cancer cell inhibition and migration by down-regulating the phosphoinositide 3-kinases (PI3K)/Akt (Protein kinase B) and tumor protein p53/B-cell lymphoma (Bcl)-2 signaling pathways as well as modification of telomerase [99,100]. This evidence concerns the gene AKT1 and breast carcinoma.